Our MD John Kelly sat down with Ausbiz to talk about Atomo’s strong growth, our solid progress with commercialising our rapid diagnostics tests and securing licensing deals with partners. Watch the interview here ...
Atomo was featured in a recent article by Biotech Dispatch regarding the TGA approval of Atomo’s rapid antigen COVID-19 test. Read Article Here ...
As WA and QLD take first steps to reopen borders, our CEO, John Kelly was asked to comment in the Australian Financial Review on how an antigen / antibody testing combo could help Australia to open up with more confidence. Read Article Here ...
Our MD, John Kelly was interviewed by Ausbiz about TGA approval for our COVID-19 rapid antigen test. Watch the Interview Here ...
Motley Fool talks about our share price gain following TGA approval of our COVID-19 rapid antigen test. Read the full article > ...
The Market Herald discusses the TGA approval for our COVID-19 rapid antigen test. Read the full article > ...
This Business News Australia discusses the benefits of our COVID-19 and the convenience of the 15-minute test. Read the full article > ...
An article by Biotech Dispatch on our expanded partnership with Access Bio to launch a rapid COVID-19 antigen test in Australia, New Zealand and India. Read the full article > ...
Our MD, John Kelly sat down with Ausbiz to discuss our rapid antigen test deal with Access Bio which will enable screening for COVID-19 acute infection and exposure at the same time. Watch the Video ...
An article by Biotech Dispatch on our agreement with DIVOC labs to launch our rapid COVID-19 antibody test in India. Read the full article > ...
An article by Motley Fool on our expanded a partnership with Access Bio to launch a rapid COVID-19 antigen test in Australia, New Zealand and India. Read the full article > ...
An article by Motley Fool on our agreement with DIVOC labs to launch our rapid COVID-19 antibody test in India. Read the full article > ...
Atomo is mentioned in this Stockhead article as one of the Aussie companies involved in the efforts against COVID-19. Read the full article > ...
An article by Stockhead talks about our FY20 results and our COVID-19 antibody tests. Read the full article > ...
Medical diagnostics company Atomo Diagnostics (AT1) has seen its revenue jump nearly 900 per cent over FY20 as demand for COVID-19 antibody tests skyrockets. Read the full article > ...
An interview with Atomo MD, John Kelly on our FY20 results and strong uplift in revenues. Watch the full interview > ...
Atomo Diagnostics (ASX: AT1) has announced that the TGA has approved its rapid SARS-CoV-2 antibody blood test for use by medical professionals in Australia. Read the full article > ...
The healthcare community and broader market initially misunderstood the role of Atomo Diagnostic's COVID-19 antibody test, with CEO John Kelly saying it is designed to be used in conjunction with the gold-standard molecular polymerase chain reaction (PCR) swabs, not as a replacement. Read the full article >...
MD and CEO discusses TGA approval for our COVID-19 antibody test in this video interview. Read the full article > ...
As the state of Victoria in Australia records its deadliest day since the COVID-19 pandemic began, reporting 17 deaths and 394 new cases, Atomo Diagnostics Ltd.’s new COVID-19 antibody test could ease pressure on health care systems. Read the full article >...
In this interview, CEO John Kelly talks about how COVID-19 antibody testing will be important to verify any future vaccine for the virus. Watch the interview > ...
An article in BioSpectrum Asia on Atomo’s agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
In this Stockhead article, CEO, John Kelly discusses why COVID-19 testing will continue for years not months, the development of a vaccine and how Atomo is focused on growing its non-COVID related businesses. Read the full article > ...
An article in BioSpace on Atomo’s agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
This article in Small Caps article talks about the agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
Atomo CEO, John Kelly talks about why Atomo developed a rapid diagnostic test for COVID-19. Read the full article > ...
Managing Director and CEO, John Kelly talks to the ASX about the inspiration behind Atomo, listing on the ASX during COVID-19 and why having the right advisors is crucial when you IPO. Watch the video and read the full interview here > ...
Managing Director and CEO, John Kelly talks to Ausbiz about Atomo’s expanded partnership with NG Biotech and securing exclusive rights to market and distribute the COVID-19 antibody test for Australia, NZ and parts of SE Asia. Watch the interview here > ...
Atomo secures exclusive rights for Australia, New Zealand and South East Asia¹ SYDNEY Australia, Thursday, 4 June 2020 – Atomo Diagnostics Limited (ASX: AT1) (Atomo) is pleased to announce it has expanded its existing COVID-19 rapid test partnership with NG Biotech, SAS (NG Biotech), which was...
Stockhead’s Tim Boreham discusses Atomo’s background and history and the benefits of its rapid blood test devices for a range of conditions including COVID-19. Read the full article > ...